Augustine Therapeutics

Augustine Therapeutics is a Belgian biotechnology company founded in 2019 and based in Leuven.

It originated as a spin-off from the Flemish Institute of Biotechnology (VIB) and KU Leuven, focusing on developing innovative therapies for complex neurological disorders. The company specializes in drug discovery, clinical trials, and precision medicine, with a mission to create first-in-class treatments that protect and regenerate axons. The company operates under a B2B model, advancing its lead programs, including AGT-100216, a selective HDAC6 inhibitor aimed at treating Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy. Augustine Therapeutics has raised over €89 million to support its research and development efforts, collaborating with various investors and academic institutions. With additional research facilities in Cambridge, Massachusetts, and Copenhagen, Denmark, Augustine is dedicated to addressing unmet medical needs in neuromuscular and neurodegenerative diseases.